-transparent.png){kind=logo}
Peripheral blood progenitor cells (PBPCs) have become the preferred means of stem cell support for high-dose chemotherapy in recent years. The biology of PBPC mobilization is complex and may be influenced by several variables. Signals from both stromal and hemopoietic cells may induce downregulation of adhesion molecules and upregulate the expression of metalloproteinases. Cytokines alone can mobilize PBPCs but a synergistic effect has been shown when they are used in conjunction with chemotherapy. Disease-specific mobilization strategies appear to have the advantage of less toxicity, greater stem cell yield, and enhanced antitumor activity. Studies have demonstrated that the number of peripheral blood CD34+ cells can be used as a predictor for the timing of apheresis and for estimating PBPC yield. Similarly the CD34+ cell dose is the strongest predictor of hematologic recovery after PBPC transplant. Age, prior radiotherapy, marrow involvement, and prior chemotherapy (especially with alkylating agents) are important factors influencing the yield of stem cells.
E Olavarria, and
E J Kanfer
December 1995,
The Canadian journal of oncology,
E Olavarria, and
E J Kanfer
January 1993,
Journal of hematotherapy,
E Olavarria, and
E J Kanfer
December 1994,
Seminars in oncology,
E Olavarria, and
E J Kanfer
February 1997,
Seminars in oncology,
E Olavarria, and
E J Kanfer
February 1994,
Blood,
E Olavarria, and
E J Kanfer
February 1998,
Clinical cancer research : an official journal of the American Association for Cancer Research,
E Olavarria, and
E J Kanfer
January 2002,
Cancer treatment and research,
E Olavarria, and
E J Kanfer
January 2014,
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
E Olavarria, and
E J Kanfer
June 1997,
Cytokines, cellular & molecular therapy,
E Olavarria, and
E J Kanfer
January 1999,
Bailliere's best practice & research. Clinical haematology,
